Revenue also topped consensus at $11.99 billion versus $11.7 billion, while adjusted operating margin improved to 22.8% amid broad segment growth.
Thermo Fisher Scientific reported a stronger-than-expected second quarter, with revenue rising 10% to $11.99 billion and adjusted earnings per share increasing 13% to $6.03, both ahead of analyst expectations. The company said growth was broad-based across all segments, including Life Sciences Solutions and Analytical Instruments. Adjusted operating margin improved to 22.8%, pointing to stronger profitability alongside the top-line gain.